Journal of asthma and allergy · 2026
Effectiveness of the P2X3 Antagonist Gefapixant for Refractory Atopic Cough: A Retrospective Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ishiura Yoshihisa, Nomura Shosaku, Ohkura Noriyuki, Hara Johsuke, Fujimura Masaki, Ito Tomoki
Аннотация
BACKGROUND: Atopic cough, arising from hyperresponsiveness of afferent airway C-fibers, is common, and cough is one of the commonest reasons for referral to respiratory clinic. Gefapixant is a first-in-class P2X3 receptor antagonist recently approved for use in patients with refractory cough to inhibit airway C-fiber activation. We conducted this study to investigate the clinical effect of gefapixant in patients with refractory atopic cough that responded only partially to azelastine monotherapy.
METHODS: This was a single-center retrospective observational study. Patients with refractory atopic cough received gefapixant. Collected retrospectively from medical records, data included cough symptom questionnaire responses and results from respiratory function tests, cough reflex sensitivity tests, and blood tests.
RESULTS: Data from 23 patients with refractory atopic cough were included in this study. Spirometry parameters, fractional exhaled nitric oxide levels, peripheral eosinophil counts, and IgE levels were unchanged after gefapixant treatment. Scores for the cough severity visual analog scale and Leicester cough questionnaire significantly improved after treatment with gefapixant (both p<0.01). Cough reflex sensitivity to inhaled capsaicin also significantly improved after treatment with gefapixant (p<0.01).
CONCLUSION: The P2X3 antagonist gefapixant appeared to improve patient-reported symptoms and cough reflex hypersensitivity in a retrospective cohort of patients with refractory atopic cough. These findings suggest P2X3 antagonists may be a treatment option for refractory atopic cough, possibly through possibly through reducing hypersensitivity of airway C fibers.
METHODS: This was a single-center retrospective observational study. Patients with refractory atopic cough received gefapixant. Collected retrospectively from medical records, data included cough symptom questionnaire responses and results from respiratory function tests, cough reflex sensitivity tests, and blood tests.
RESULTS: Data from 23 patients with refractory atopic cough were included in this study. Spirometry parameters, fractional exhaled nitric oxide levels, peripheral eosinophil counts, and IgE levels were unchanged after gefapixant treatment. Scores for the cough severity visual analog scale and Leicester cough questionnaire significantly improved after treatment with gefapixant (both p<0.01). Cough reflex sensitivity to inhaled capsaicin also significantly improved after treatment with gefapixant (p<0.01).
CONCLUSION: The P2X3 antagonist gefapixant appeared to improve patient-reported symptoms and cough reflex hypersensitivity in a retrospective cohort of patients with refractory atopic cough. These findings suggest P2X3 antagonists may be a treatment option for refractory atopic cough, possibly through possibly through reducing hypersensitivity of airway C fibers.